MOTS-C dosage & cycles.

Daily dosage and frequency

MOTS-MET is testing subcutaneous MOTS-C once daily for 12 weeks. The registered phase 2a trial plans to enroll 120 adults with prediabetes and overweight or obesity. Its public record specifies a fixed daily amount but does not publish the milligram dose. It is recruiting, with no results posted. [1]

For the 40 mg vial, a final solution volume of 2 mL gives 20 mg/mL. At that concentration, a 5 mg amount occupies 0.25 mL, equal to 25 units on a U-100 syringe scale. Five milligrams is the worked calculation example used here; it is not the unpublished MOTS-MET dose or a recommended treatment schedule. [2]

The vial and pen totals describe all the peptide in each container. They are not amounts to administer in one session. The main MOTS-C guide explains the compound and its research; the calculations below convert a separately specified amount into liquid volume.

Reconstituting a 40 mg MOTS-C vial

The vial holds 40 mg of dry powder in a 3 mL container. Its concentration is set by the final prepared solution volume. Forty milligrams divided by 2 mL equals 20 mg/mL. The container's 3 mL capacity is separate from the amount of solution actually prepared. [2]

Use the compatible diluent and final volume specified by the preparation method. For prescribed administration, the dispensing professional supplies the sterile preparation instructions and use-by period. The 2 mL example is concentration arithmetic; it does not establish a sterile formulation or select a diluent.

Handling and storage follow the product specifications, matching powder-lot report and general CDC aseptic-preparation guidance. [2] [3] [4]

More liquid lowers the concentration without increasing the total peptide. For example, the mathematical concentration at a final 1 mL would be 40 mg/mL, twice the concentration of the 2 mL example. That changes the volume needed for a given amount. It does not double the vial's 40 mg content or establish that a different formulation is suitable.

General subcutaneous injection sites

Subcutaneous administration places medication in the fatty layer beneath the skin. General medication guidance identifies the abdomen, outer upper thigh and side or back of the upper arm. On the abdomen, leave at least 2 inches, about 5 cm, around the belly button. [5]

Rotate locations and choose healthy skin, avoiding red, bruised, swollen or scarred areas. The graphic shows general medication sites for a prescribed subcutaneous preparation. It is not a guide to injecting a joint, tendon or muscle.

Morning, evening, meals and exercise

The public MOTS-MET record specifies once-daily administration without a morning, evening, meal or workout timing instruction. It therefore does not support a claim that fasting injections or taking MOTS-C immediately before exercise works better. Participants also receive standardized lifestyle counseling. [1]

The 2021 exercise study measured changes in people's own MOTS-C during and after exercise; its human participants were not given the peptide. A rise in a natural blood marker after a workout does not determine when an injected product should be used. The results article separates those observations from administered-peptide studies. [6]

A human injection half-life has also not been established in the published evidence reviewed by FDA. Laboratory breakdown of MOTS-C in a blood sample cannot provide an exact repeat-injection interval. A registered once-daily schedule describes the trial design, rather than proving that every effect lasts 24 hours. [7]

MOTS-C dosage calculator

Enter vial milligrams, final solution millilitres and the amount to measure. The preset uses 40 mg, 2 mL and a 5 mg target. It returns 20 mg/mL, 0.25 mL, 25 U-100 units and eight mathematical portions.

The conversions are: concentration = total mg ÷ final mL; liquid volume = target mg ÷ mg/mL; U-100 scale units = mL × 100. One milligram equals 1,000 micrograms, so a 5 mg target and a 5,000 mcg target produce the same answer.

These are measurement examples, not a menu of treatment doses. U-100 units describe a volume scale: 100 units equals 1 mL. They are not milligrams of MOTS-C. A syringe must have markings that can represent the calculated volume; rounding a halfway mark changes the measured amount.

Daily and weekly totals

Total amount equals amount per administration multiplied by the number of administrations. Keep that count separate from the calendar. Four 5 mg portions contain 20 mg whether they are measured across four days or a longer period; the timing must come from the independently specified plan.

For any once-daily schedule, the daily total is the amount per administration and the seven-day total is seven times that amount. A separately specified 5 mg once-daily plan would therefore total 35 mg in seven days. That is conditional arithmetic, not a claim about the trial's undisclosed dose.

Changing only the concentration changes the liquid volume, not these milligram totals. Conversely, keeping the same syringe volume after changing concentration changes the amount administered. Recalculate from the actual concentration whenever the prepared volume or product format changes.

Cycle length and time off

The native MOTS-C trial has a 12-week treatment period and four weeks of follow-up. Twelve weeks of once-daily administration represents 84 planned administrations. Follow-up continues through week 16 to collect safety information. The follow-up period is not an established four-week break before restarting another cycle. [1]

A four-week study often discussed alongside MOTS-C used CB4211, a modified analog. Its sponsor reported 25 mg subcutaneously once daily for four weeks in a phase 1b study. That amount and duration belong to CB4211 and cannot be transferred to the 40 mg native MOTS-C vial or the 30 mg pen. [8]

For quantity planning, four, eight and twelve weeks contain 28, 56 and 84 days. If an independently prescribed daily amount is represented by D milligrams, the corresponding totals are 28D, 56D and 84D milligrams. This keeps duration calculations usable without inventing the clinical amount.

There is no completed native MOTS-C human trial here establishing a maintenance phase, a repeat-cycle interval or a taper. Duration should not be extended simply to empty a container. The side-effects article explains the safety evidence and formulation issues that matter when evaluating longer exposure. [7]

Measuring amounts in the 30 mg pen

The pen contains 30 mg in 3 mL at 10 mg/mL. It is already mixed with water and 0.9% benzyl alcohol. No reconstitution or added water is required. Its concentration is half the 20 mg/mL vial example, so the same milligram amount occupies twice the liquid volume. [2]

The table converts mass into solution volume. Use the pen's own device instructions to set and deliver the specified amount; syringe-scale markings are not pen-click instructions. Keep the pen at 2–8°C in its carton, protected from light, and do not freeze it. [2]

The buying page compares the two formats, their preparation requirements, product photographs and the matching powder-lot certificate.

Total milligrams, vials and pens needed

One 40 mg vial contains eight mathematical 5 mg portions; one 30 mg pen contains six. For another target amount, divide 40 mg or 30 mg by that amount. A 2.5 mg example gives sixteen portions per vial and twelve per pen. These are nominal mass calculations before preparation, transfer or device losses. [2]

Calculate the number of containers by dividing the total milligrams needed by the container total and rounding up to a whole container. For 60 mg, 60 ÷ 40 = 1.5 vials, so two vials supply enough nominal peptide. The same 60 mg equals exactly two 30 mg pens.

Mathematical portions do not extend a preparation's use-by period. Container totals also exclude priming and residual liquid that a delivery device cannot dispense. Plan quantities from the actual preparation and device instructions as well as the milligram calculation.